Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
416. |
ECCT/21/05/07 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern |
Principal Investigator(s) 1. Grace Mboya Mugure Site(s) in Kenya 1. KEMRI CGHR Kisumu Clinical Research Site (Kisumu county) |
View |
417. |
ECCT/22/01/02 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern |
Principal Investigator(s) 1. Ben Madeke Andagalu Site(s) in Kenya 1. KEMRI -USAMRD-A, Kombewa Clinical Research Centre (Kisumu county) 2. KEMRI-CGHR (Kisumu county) |
View |
418. |
ECCT/10/03/03 | High-Dose Fluconazole Treatment in AIDS-Associated CM A5225/HiFLAC: A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
View |
419. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
View |
420. |
ECCT/20/03/01 | GlycoShig3 A Phase 2a age descending study to investigate the safety and immunogenicity of the SF2a-TT15 synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a in adult, children and infant target population in endemic countries. |
Principal Investigator(s) 1. Fredrick Kipyegon Sawe Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Kericho |
View |